Gastroparesis Drugs Market: Ability to Offer End to End Solutions to Drive Market Growth

The Gastroparesis Market is valued at $ 4,667 million in 2016 and is expected to reach $ 6,486 million at an annual average growth rate of 4.7% from 2017 to 2023.

Gastroparesis affects the normal spontaneous movement of the stomach muscles and therefore interferes with normal digestion, causing nausea, vomiting, blood sugar levels and nutritional problems. Gastric paralysis can be caused by diabetes or after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, and anti-vomiting drugs have been developed to treat gastroparesis.

The major factors leading to the growth of the worldwide peritoneal paralysis drug market are the number of operations that can lead to postoperative gastroparesis, increase in the diabetic population, introduction of new drugs, and increase in the elderly population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to curb market growth. On the contrary, the untapped market potential of emerging markets such as China and India and the development of new gastroparesis preventative drugs are expected to provide a good opportunity for market participants.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4153?utm_source=sy-Openpr

The list of key players profiled in this report include
 Allergan Plc.
 Abbott Laboratories (Abbott Arzneimittel GmbH)
 AstraZeneca Plc.
 Cadila Pharmaceuticals Ltd.
 ETX Pharma Inc
 Evoke Pharma
 GlaxoSmithKline Plc.
 Neurogastrx Inc.
 Valeant Pharmaceuticals International Inc.
 Theravance Biopharma.

Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company Ltd.

The prokinetic agent segment accounted for the largest portion in 2016 due to its high utility, applicability, and the availability of exercise promoters for the treatment of gastroparesis. In addition, botulinum toxin injections are expected to grow at a CAGR of 5.6% from 2017 to 2023 and are expected to remain toxic throughout the forecast period.

The use of gastric paralytic drugs for idiopathic gastrointestinal paralysis is high, but the postoperative paralytic segment is expected to grow at a CAGR of 5.2% over the forecast period. This is because of the increased incidence of various types of surgeries, such as transplant surgery, resulting in post-operative abdominal palsy.

Buy Now (Data Pack Available with Discounted Price): @ https://www.alliedmarketresearch.com/checkout/368248?utm_source=sy-Openpr

Key findings of the Gastroparesis Drugs Market:
• Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016.
• Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023.
• Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016.
• Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016.
• Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023

The North American market has accounted for nearly one-third of the global market as a major revenue contributor to the global peritonitis paralysis market. This seems to be due to the early use of gastric paralytic drugs and the high use of this drug due to an increased incidence of gastric paralysis. However, the Asia-Pacific region is expected to grow at a CAGR of 5.5% per annum due to rising costs, higher spending on healthcare, and increased awareness of gastroparesis drugs during the study period.

Access Full Summery @ https://www.alliedmarketresearch.com/gastroparesis-drugs-market?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.